Back to Central Nervous System Drugs
Capsules: 5 mg
In the tuberoinfunibular process dopaminergic neurons influence the secretion of prolactin from the anterior pituitary by secreting dopamine, an inhibitor of prolactin. In the corpus striatum dopaminergic neurons help to control motor function.
Sudies have shown that bromocriptine induces long lasting stereotyped behavior in rodents and turning behavior in rats having unilateral lesions in the substantia nigra (a structure located in the midbrain that produces dopamine and that plays a part in motor control). Actions such as these, characteristically produced by dopamine, are inhibited by dopamine antagonists and point towards a direct action of bromocriptine on striatal dopamine receptors.
Bromocriptine mesylate is both a nonhormonal, nonestrogenic, agent that inhibits the secretion of prolactin with little to no effect on other pituitary hormones. However, because the drug does inhibit lactation it is not recommended that it be given to a female rat that is or will be nursing a litter.
Bromocriptine mesylate is metabolized in the gastrointestinal tract and liver. More than 90% of the absorbed dose undergoes first-pass metabolism. The major route of excretion of bromocriptine is primarily in bile. Nearly all the dose is excreted in feces with only about 2-6% of the oral dose excreted via the urine. The elimination half-life of bromocriptine is approximately 6 hours.
Bromocriptine though similar to cabergoline has less selectivity for dopamine D2 receptors, and with a shorter half- life requires a more frequent dosing regimen than cabergoline. Side effects are also reportedly less with cabergoline than with bromocriptine. Expense, dosing frequency and compliance, availability, and side effects may play a factor in choosing whether bromocriptine or cabergoline is more suitable when treating the pet rat.
Or, where there has been removal of existing benign (adenoma) mammary tumors, the use of a prolactin secretion inhibitor such as bromocriptine may be beneficial in the prevention of new benign tumor growth
Plasma levels of bromocriptine may increase when co-administered with erythromycin or ketoconazole.
CV: low blood pressure, abnormal/irregular heart beat, valvulopathy, pericardial fibrosis
Respiratory: nasal congestion, pleural/pulmonary fibrosis
GI: nausea ( in rats this seen by inappetence and pica), decreased appetite, dry mouth, diarrhea, constipation
GU: urine retention
Hepatic: & nbsp; liver impairment
Skin: pruitus (itching), coolness & pallor of feet and tail.
Other: behavioral changes, inhibits lactation
*Note: Overdosing can result in acute toxicity. The side effects of bromocriptine are primarily dose related. Decreasing the dosage may help to reduce those side effects.
3 mg/kg per day 36
Posted on September 4, 2012, 11:58,
Last updated on June 20, 2013, 14:43
| Central Nervous System Drugs